Tokai Halts Phase 3 Trial of Prostate Cancer Drug Galeterone; Panel Says It’s Unlikely to Reach Primary Endpoint
News
Tokai Pharmaceuticals (Tokai) dropped a bombshell Tuesday when it announced it will discontinue its flagship ARMOR3-SV clinical trial, a pivotal Phase 3 study comparing the efficacy of Tokai’s prostate cancer drug ... Read more